companyprofile

Actions

Middle East Pharmaceutical Industries Co.

4016
AVALON PHARMA
Add To Watchlist
In your Watchlist
Add To Watchlist
  • Main Market
  • Pharma, Biotech & Life Science

Stats Overview

  • Prev. Close 126.20
  • Open 127.60
  • High 127.60
  • Low 124.20
  • No. of Trades 1,332
  • Avg. Trade size* 48
  • Volume Traded 63,544
  • Value Traded (SAR) 7,967,257.00

Performance

AVALON PHARMA
-0.60 ( -0.48% )
Compare
Name Price Change %
Middle East Pharmaceutical Industries Co. 127.60 -0.48%
Note: Prices are delayed minimum 5 minutes
  • *Average Trade Size = Cumulative / # of Trades
  • **52 Week Price Change =   (Current Price - Price year ago) / Price year ago x 100
  • Historical prices & volume traded data are adjusted to account for all corporate actions.
  • MO: Market Order

Trade Updates

Last Trade

Price
125.60
% Change
-0.48
Volume Traded
130

Best Bid

Price 125.60
Volume 330

Best Offer

Price 125.80
Volume 2

52 WEEK

High
197.60
2024/03/03
Low
90.20
2024/02/27
Change**
0.0

PERFORMANCE

Start of Year
106.6
Year ago
3 Years ago

Compare Selected

Select a Maximum of 5 Companies

Compare Selected

LoginPortletPopupv2

Actions

AddtoWatchlistv2

Actions

Add to watchlist

AnnouncmentandCorporateAction

Actions
Jump To :
  • Announcements & Corporate Actions
  • Dividends
  • Financials
  • Shareholding
  • Peer Comparison
  • Company Profile

Announcements

  • The Board of Directors of Middle East Pharmaceutical Industries Co. invites shareholders to Attend the Extraordinary General Assembly Meeting (First Meeting) through Modern Means of Technology

    4016
    AVALON PHARMA -0.48 %
    1445/12/03     09/06/2024 20:08:48
  • Middle East Pharmaceutical Industries Co. announces its Interim Financial results for the Period Ending on 2024-03-31 ( Three Months )

    4016
    AVALON PHARMA -0.48 %
    1445/11/11     19/05/2024 09:46:54
  • Middle East Pharmaceutical Industries Company “Avalon Pharma” announces the approval of the Saudi Food and Drug Authority (SFDA) to register new production lines at the company's Factory No. 2 in Riyadh

    4016
    AVALON PHARMA -0.48 %
    1445/10/27     06/05/2024 09:08:08
  • Middle East Pharmaceutical Industries Co. announces its Annual Financial results for the period ending on 2023-12-31

    4016
    AVALON PHARMA -0.48 %
    1445/09/15     25/03/2024 15:42:21
View All

Corporate Actions

Upcoming Events

    Past Events

      Jump To :
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Dividends

      Announced Date Eligibility Date Distribution Date Distribution Way Dividend Amount

      CompanyProfilev2Financials

      Actions
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Financials

      • FINANCIAL INFORMATION
      • FINANCIAL STATEMENTS AND REPORTS
      • Annually
      • Quarterly
      Balance Sheet 2023-12-31
      Total Assets
      444,898.75
      - - -
      Total Liabilities
      138,499.23
      - - -
      Total Shareholders Equity (After Deducting the Minority Equity)
      306,399.52
      - - -
      Total Liabilities and Shareholders Equity
      444,898.75
      - - -
      Statement of Income 2023-12-31
      Total Revenue (Sales/Operating)
      338,439.7
      - - -
      Net Profit (Loss) before Zakat and Tax
      71,438.23
      - - -
      Zakat and Income Tax
      -5,610.88
      - - -
      Net Profit (Loss) after Zakat and Tax
      65,827.35
      - - -
      Total Comprehensive Income
      62,125.89
      - - -
      Profit (Loss) per Share
      3.29
      - - -
      Cash Flow 2023-12-31
      Net Cash From Operating Activities
      92,659.34
      - - -
      Net Cash From Investing Activities
      -30,833.35
      - - -
      Net Cash From Financing Activities
      -70,509.64
      - - -
      Cash and Cash Equivalents, Beginning of the Period
      23,790.84
      - - -
      Cash and Cash Equivalents, End of the Period
      15,107.19
      - - -
      All Figures in Thousands
      All Currency In SAR
      Last Update Date 2024-03-25

      The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.

      Balance Sheet
      Total Assets
      Total Liabilities
      Total Shareholders Equity (After Deducting the Minority Equity)
      Total Liabilities and Shareholders Equity
      Statement of Income
      Total Revenue (Sales/Operating)
      Net Profit (Loss) before Zakat and Tax
      Zakat and Income Tax
      Net Profit (Loss) after Zakat and Tax
      Total Comprehensive Income
      Profit (Loss) per Share
      Cash Flow
      Net Cash From Operating Activities
      Net Cash From Investing Activities
      Net Cash From Financing Activities
      Cash and Cash Equivalents, Beginning of the Period
      Cash and Cash Equivalents, End of the Period
      All Figures in
      All Currency In
      Last Update Date

      The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate. The above information does not replace detailed financial statements, as detailed financial statements are the reliable source that must be consulted to obtain accurate financial information.

      Display Previous Periods
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Shareholding Information

      • Board Of Directors
      • Foreign Ownership
      • Substantial Shareholders
      Time Period
      -
      Search
      Trading Date Shareholders Designation Shares Held Trading Day Shares Held Prev Trading Day Change
      • The listed company (Publisher) shall be responsible for the accuracy of the published information pertaining to the ownership of the Board of Directors, Chief Executive Officer or highest executive position, and the Chief Financial Officer. The listed company shall also be responsible for updating these information thereof. Therefore, the Saudi Stock Exchange (Tadawul) shall not be liable for the information contained therein, nor for any consequences that may result from the said information.
      for
      subs
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Peer Comparison

      • Table
      • Graphical
      Add Company

      Compare Selected

      Select a Maximum of 5 Companies

      Company Apply
      Middle East Pharmaceutical Industries Co.
      Price 125.60
      Market Cap (SAR MN) 2,524
      P/E Ratio 33.34
      Index Name Index Level 1D Return
      Middle East Pharmaceutical Industries Co. %
      Jump To:
      • Announcements & Corporate Actions
      • Dividends
      • Financials
      • Shareholding
      • Peer Comparison
      • Company Profile

      Company Profile

      Company overview

      Avalon Pharma develops, manufactures, markets and distributes a wide range of generic medicines and pharmaceuticals in the Kingdom of Saudi Arabia and abroad through a diversified, high-quality product portfolio covering several therapeutic categories.

      Company History

      Middle East Pharmaceutical Industries Co. was established as a limited liability company under Commercial Registration number (1010150538) issued in Riyadh on 02/04/1419H (corresponding to 26/07/1998G). In 2022G, the company was converted into a Joint Stock on 13/09/1443H (corresponding to 14/04/2022G).

      Company Bylaws

      Click here

      Equity Profile

      • Authorized Capital (SAR) 200,000,000
      • Issued Shares 20,000,000
      • Paid Capital (SAR) 200,000,000
      • Par Value/Share 10
      • Paid Up Value/Share 10

      Last Update :2024-02-26

      Investment limits

      There are no investment limits on the company's shares as per the amended Rules for Qualified Foreign Financial Institutions Investment in Listed Securities and Instructions for the Foreign Strategic Investors Ownership in Listed Companies based on Company's bylaw and the issued Instructions by related regulators and supervisory authorities.

       

      • Company Details
      • BOARD OF DIRECTORS AND SENIOR EXECUTIVES INFORMATION
      • Date Established

        1998/06/29

      • Financial Year End

        31/12

      • Listing Date

        2024/02/27

      • External Auditors

        [KPMG Professional Consulting]

      • ISIN CODE

        SA160G51UO10

      • Number of Employees

        541

      • Chairman

        Ahmed Shaher Ahmed Altabbaa
        Non - Executive

        Ahmed Shaher Ahmed Altabbaa
        • BD Session Start
          2022-04-10
          Designation
          Chairman
        • BD Session End
          2026-04-09
          Classification
          Non - Executive
        • Qualification
          Holds a bachelor degree in economics from the American University in Washington State, USA, in 1994
        Companies Membership
        • Memebrship Name
          Jordan Saudi E-Commerce Company
          Start Date
          -
        • Memebrship Character
          Vice President
          End Date
          -
      • Board of Directors

        Hisham Mohammed Mahmoud Attar Deputy Chairman - Independent

        Hisham Mohammed Mahmoud Attar
        • BD Session Start
          2023-09-13
          Designation
          Board of Directors
        • BD Session End
          2026-04-09
          Classification
          Deputy Chairman - Independent
        • Qualification
          Holds a bachelor's degree in business economics and organization of public and private sector from Brown University in Rhode Island, USA in 2004.
        Companies Membership
        • Memebrship Name
          The Saudi Technology Development and Investment Company (TAQNIA)
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Tejoury Company
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Arab Bank
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Saudi Jordanian Investment Fund Co
          Start Date
          -
        • Memebrship Character
          Chairman of the board
          End Date
          -
        • Memebrship Name
          KC Agro
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -

        Mohamed Maher MohammedLotfi Alghannam Executive

        Mohamed Maher MohammedLotfi Alghannam
        • BD Session Start
          2022-04-10
          Designation
          Board of Directors
        • BD Session End
          2026-04-09
          Classification
          Executive
        • Qualification
          Holds a master degree in business administration from the University of Central California, California, USA in 2018 Holds a bachelor degree in business administration from Damascus University in Syria in 2009

        Faisal Sulaiman Mohamed Aljaman Independent

        Faisal Sulaiman Mohamed Aljaman
        • BD Session Start
          2022-04-10
          Designation
          Board of Directors
        • BD Session End
          2026-04-09
          Classification
          Independent
        • Qualification
          Holds a bachelor degree in computer technology from Brunel University in the United Kingdom in 1978
        Companies Membership
        • Memebrship Name
          Al Eisai Motors Company
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Arab Tile Company
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Alshamel Marketing Company
          Start Date
          -
        • Memebrship Character
          Chairman of the board
          End Date
          -
        • Memebrship Name
          Tawkelat Financing
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -

        Omar Mohammed Saib Abdulqader Al Jaroudi Independent

        Omar Mohammed Saib Abdulqader Al Jaroudi
        • BD Session Start
          2023-03-05
          Designation
          Board of Directors
        • BD Session End
          2026-04-09
          Classification
          Independent
        • Qualification
          Holds a master degree in economics from Syracuse University New York USA in 1984 Holds a bachelor degree in business administration from the American University of Beirut Lebanon in 1983
        Companies Membership
        • Memebrship Name
          Yamam Al-Mustaqbal Company
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Acacia Real Estate Development Company
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Al Bani Real Estate Development Company
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          United Shareholders Company
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
        • Memebrship Name
          Quintillion UK Hotels Company (Home House)
          Start Date
          -
        • Memebrship Character
          Board member
          End Date
          -
      • Senior Executives

        Mohamed Maher MohammedLotfi Alghannam CEO

      Mohamed Maher MohammedLotfi Alghannam
      • BD Session Start
        2000-09-01
        Designation
        Senior Executives
      • BD Session End
        -
        Classification
        CEO

      Investor Relations

      Contact Name:

      Investor Relations Department

      Company Address:

      Second Industrial City, Riyadh P.B. 3800 Riyadh 14331

      Contact Details:

      Telephone: 2653948 11 966+
      Fax : 2654723 11 966+
      Email : investor.relations@avalon.com.sa

      Company Website:

      www.avalonpharmaceutical.com


      Name Of Subsidiary Percentage Of Property Main Business Location Of Operation Country Of Operation
      Avalon Pharma UK Holding Ltd 100.00% Manufacturing of medicine, medical creams, non-medical creams, and ointments United Kingdom United Kingdom
      Add To Watchlist
      In your Watchlist
      Add To Watchlist

      The Capital Market Authority and Saudi Exchange take no responsibility for the contents of these disclosures, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of these disclosures, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.